Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results, is ...

With this approval, the Catamaran is now indicated to treat the SI joint as either a stand-alone treatment or to augment a spinal fusion. "The FDA has cleared the Catamaran SI Joint Fusion System ...

“We are excited to begin the journey of accelerating market penetration of Nevro’s differentiated high-frequency technology and bringing a much-needed treatment option to patients suffering ...

Tenon Medical (TNON) announced that the FDA has provided clearance of an expanded indication for the Catamaran SI Joint Fusion System for use in augmenting thoracolumbar fusion. With this approval ...

Image Source: Zacks Investment Research Market Expansion Into SI Joint Fusion: Nevro's expansion into the sacroiliac (SI) ...